memantine hydrochloride / donepezil hydrochloride
On 18 October 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Acrescent, intended for the treatment of moderate to moderately severe Alzheimer’s disease in patients who are already taking memantine and donepezil.
The company that applied for authorisation is H. Lundbeck A/S, Denmark.
Questions and answers on the refusal of the marketing authorisation for Acrescent (PDF/75.45 KB)Adopted
First published: 19/10/2012
Last updated: 11/03/2013
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
H. Lundbeck A/S
|Date of opinion||
|Date of refusal of marketing authorisation||